Unilever PLC
ULUnilever PLC's earnings have outrun its stock. EPS grew +67.4% in a year against a −5.8% price move.
The sharpest disagreement: annual EPS moved +67.4% against a −5.8% price move — the market has not yet caught up with the delivery.
The price is topping out (1 weeks in). Underneath, the last four quarters read improving — profit +18.8% year on year, and 145% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Unilever PLC trades at $64.1, losing momentum at the top and 1 weeks into that stage. That is +0.6% against its own 200-day average. It sits at 45% of a 52-week range of $55 to $75. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is losing momentum at the top — week 1 of stage 3. At $64.1 it trades +0.6% versus its 200-day average and sits at 45% of its 52-week range ($55–$75).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +20% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Unilever PLC trades at 13.0× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.0× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +67.4% against a −5.8% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Unilever PLC reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −3.8% | −5.6% | — | — |
| Profit | +2.8% | −9.1% | — | — |
| EPS | +67.4% | +8.7% | — | — |
| Stock price | −5.8% | +3.2% | +0.1% | +2.1% |
4-Factor Sector Score
48.4/100 — rank 20 of 20 in Household & Personal Products · 43% evidence confidence · provisional, ranked below fully-evidenced peers
Unilever PLC scores 48.4 out of 100 against the 20 companies it is compared with in Household & Personal Products, ranking 20. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 18.2 + 14.3 + 11 + 4.9 = 48.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Unilever PLC reported $20.4 B of revenue in the Dec 25 quarter, −31.2% year on year. Over 4 years it has compounded at −0.9% a year. The last full year, FY25, came in at $50.5 B. The last four reported quarters add to $111 B.
FY25 revenue came in at $50.5 B (−3.8% on the year), capping 4 years at −0.9% compound. The latest quarter (Dec 25) printed $20.4 B, −31.2% year on year.
Pace check: the last four quarters averaged +1.8% growth against the decade's −0.9% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Unilever PLC's operating margin is 18.3% in the Dec 25 quarter, +6.7 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +1.9 percentage points. Across 5 fiscal years the operating margin has ranged 16.6% to 17.9%.
The latest quarter's operating margin is 18.3%, +6.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 16.6%–17.9%, and FY25's 17.9% is the top of that band — a record year.
Why the margin moved: operating margin went +1.9 pp year on year while gross margin went +0.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Unilever PLC earned $2.4 B of net profit in the Dec 25 quarter, +18.8% year on year. Full-year FY25 profit was $6.2 B. The 4-year compound rate is −1.6%. That is 11.8% of the quarter's revenue. The same quarter a year earlier earned $2.8 B.
Dec 25 profit was $2.4 B, +18.8% year on year. On the full year, FY25 printed $6.2 B (+2.8%), and the 4-year compound rate is −1.6%.
Why profit moved: revenue contributed −31.2% and the margin +6.7 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −2.3% vs revenue +1.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 145% of Unilever PLC's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $8.3 B of operating cash against $6.2 B of profit. After $1.4 B of capital spending, $6.9 B was left as free cash.
FY25: operating cash of $8.3 B against reported profit of $6.2 B, leaving free cash of $6.9 B after $1.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 145% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Unilever PLC does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $4.0 B over the last 3 years. Averaged over those years that is 2.6% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $4.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Unilever PLC earns a ROE of 35% in FY25. That is up from a trough of 27% in FY24. Return on invested capital clears the cost of that capital by +10.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.3% net margin on 0.72× asset turns.
FY25 ROE is 35%, recovered from a FY24 trough of 27% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 12.3% net margin × 0.72× asset turns × 4.01× balance-sheet leverage ≈ 35.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 15.8% − 5.8% = a +10.0 pp spread. The 5.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Unilever PLC pays no dividend. Across the last 8 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Unilever PLC does not currently pay a dividend. Across the last 8 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Debt-to-equity is 1.75 at the latest reading — carrying real leverage; a full borrowings history is not in our numbers.
We hold only the latest reading here: a debt-to-equity of 1.75 — a level of leverage that amplifies both the returns above and the risk. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Unilever PLC, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 0.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Unilever PLC: the Z-score reads 3.07. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.07 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.07.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Helen of Troy LimitedHELE | 67.6/100Favorable setup71% evidence | LEADER | 24.3/35 Revenue -2.5% · PAT 100% · OPM change 124.5 pp 71% evidence | 12.4/25 ROCE 3.2% · OPM 15% 76% evidence | 15.8/20 P/E 10.2× · PEG 0.42 65% evidence | 15.1/20 RS sector 16.7% · RS bench 16.7% · 1Y 29.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.3 + 12.4 + 15.8 + 15.1 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kenvue Inc.KVUE | 63.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 24.5/35 Revenue -0.1% · PAT 53.6% · OPM change 4.7 pp 83% evidence | 15.0/25 ROCE 3.8% · OPM 19.6% 76% evidence | 14.9/20 P/E 20.6× · PEG 0.38 65% evidence | 9.5/20 RS sector -1.5% · RS bench -1.6% · 1Y -8.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 15 + 14.9 + 9.5 = 63.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Interparfums, Inc.IPAR | 59.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 15.6/35 Revenue 1.8% · PAT 1.5% · OPM change -0.7 pp 83% evidence | 15.8/25 ROCE 6.3% · OPM 21.5% 76% evidence | 9.9/20 P/E 17.2× · PEG 1.99 65% evidence | 18.5/20 RS sector 17.8% · RS bench 17.4% · 1Y 11%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 15.8 + 9.9 + 18.5 = 59.8 · Decision use: Price leads the evidence: RS versus the benchmark is 17.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Newell Brands Inc.NWL | 56.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence | 8.4/25 ROCE 3.3% · OPM 2.2% 76% evidence | 9.6/20 P/E 27.8× · PEG — 15% evidence | 19.4/20 RS sector 22.9% · RS bench 21.7% · 1Y 25.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 8.4 + 9.6 + 19.4 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5The Clorox CompanyCLX | 54.4/100Mixed-positive evidence81% evidence | TURNING | 21.1/35 Revenue -3.7% · PAT 8.6% · OPM change 2.7 pp 83% evidence | 15.3/25 ROCE 8.7% · OPM 17.3% 76% evidence | 11.9/20 P/E 16.8× · PEG 1.59 65% evidence | 6.1/20 RS sector -12.3% · RS bench -12.9% · 1Y -16.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 15.3 + 11.9 + 6.1 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Spectrum Brands Holdings, Inc.SPB | 52.0/100Mixed-positive evidence81% evidence | TURNING | 21.5/35 Revenue -3.7% · PAT 100% · OPM change 3.2 pp 83% evidence | 8.2/25 ROCE 1.5% · OPM 6.1% 76% evidence | 9.6/20 P/E 14× · PEG 2.17 65% evidence | 12.7/20 RS sector 16.8% · RS bench 17.9% · 1Y 61.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8.2 + 9.6 + 12.7 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Kimberly-Clark CorporationKMB | 51.7/100Mixed-positive evidence81% evidence | BREAKING OUT | 19.5/35 Revenue 0.1% · PAT -18.8% · OPM change 2.5 pp 83% evidence | 16.3/25 ROCE 7.7% · OPM 18.1% 76% evidence | 8.1/20 P/E 15.1× · PEG 2.35 65% evidence | 7.8/20 RS sector -7.1% · RS bench -7.7% · 1Y -18.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 16.3 + 8.1 + 7.8 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Magnera CorporationMAGN | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.7/35 Revenue 35.3% · PAT — · OPM change 1.6 pp 62% evidence | 5.7/25 ROCE 0.5% · OPM 2.1% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 12.4/20 RS sector 2.6% · RS bench 2.3% · 1Y 7.7%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 5.7 + 11.2 + 12.4 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Church & Dwight Co., Inc.CHD | 49.3/100Thin evidence · provisional58% evidence | TURNING | 17.7/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 13.6/25 ROCE 3.6% · OPM 19.8% 76% evidence | 9.4/20 P/E 31.2× · PEG — 15% evidence | 8.6/20 RS sector -0.9% · RS bench -0.8% · 1Y 13.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13.6 + 9.4 + 8.6 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Colgate-Palmolive CompanyCL | 47.3/100Thin evidence · provisional58% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -3.8 pp 45% evidence | 16.7/25 ROCE 9.5% · OPM 18.1% 76% evidence | 9.3/20 P/E 36.4× · PEG — 15% evidence | 6.1/20 RS sector -3.3% · RS bench -3.1% · 1Y 9.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 16.7 + 9.3 + 6.1 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11The Procter & Gamble CompanyPG | 45.5/100Thin evidence · provisional58% evidence | BASING | 16.7/35 Revenue — · PAT — · OPM change -1.5 pp 45% evidence | 15.8/25 ROCE 4.5% · OPM 21.5% 76% evidence | 9.8/20 P/E 22.2× · PEG — 15% evidence | 3.2/20 RS sector -11.2% · RS bench -11.4% · 1Y -3.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 15.8 + 9.8 + 3.2 = 45.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Acme United CorporationACU | 43.6/100Mixed-negative evidence75% evidence | TURNING | 13.9/35 Revenue 4.1% · PAT 0% · OPM change -2 pp 83% evidence | 9.1/25 ROCE 1.1% · OPM 3.3% 76% evidence | 6.0/20 P/E 19.4× · PEG 2.81 65% evidence | 14.6/20 RS sector 16.2% · RS bench 16.3% · 1Y 36.3%3 of 12 weeks ahead 70% evidence |
| Exact sum: 13.9 + 9.1 + 6 + 14.6 = 43.6 · Decision use: Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Edgewell Personal Care CompanyEPC | 43.0/100Mixed-negative evidence65% evidence | BREAKING OUT | 9.1/35 Revenue 0.4% · PAT -139.1% · OPM change -6 pp 83% evidence | 8.3/25 ROCE 0.6% · OPM 3.5% 76% evidence | 9.1/20 P/E 38.4× · PEG — 15% evidence | 16.5/20 RS sector 21.1% · RS bench 20.9% · 1Y 29.5%7 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 8.3 + 9.1 + 16.5 = 43 · Decision use: Price leads the evidence: RS versus the benchmark is 20.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Nu Skin Enterprises, Inc.NUS | 39.4/100Thin evidence · provisional58% evidence | BASING | 18.2/35 Revenue -14.2% · PAT — · OPM change 4 pp 62% evidence | 6.2/25 ROCE 0.4% · OPM 1.3% 76% evidence | 11.5/20 P/E 6.6× · PEG — 15% evidence | 3.5/20 RS sector -44.5% · RS bench -45.4% · 1Y -40.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.2 + 6.2 + 11.5 + 3.5 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15The Honest Company, Inc.HNST | 36.8/100Thin evidence · provisional58% evidence | FADING | 9.0/35 Revenue -9.5% · PAT — · OPM change -3.4 pp 62% evidence | 4.7/25 ROCE -0.4% · OPM -0.8% 76% evidence | 9.0/20 P/E 61.3× · PEG — 15% evidence | 14.1/20 RS sector 8.6% · RS bench 8.3% · 1Y -1.3%8 of 12 weeks ahead 70% evidence |
| Exact sum: 9 + 4.7 + 9 + 14.1 = 36.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16The Estée Lauder Companies Inc.EL | 34.1/100Adverse evidence64% evidence | ASLEEP | 14.7/35 Revenue 0.3% · PAT — · OPM change -1.9 pp 62% evidence | 9.4/25 ROCE 1.7% · OPM 6.7% 76% evidence | 8.7/20 P/E 178× · PEG — 15% evidence | 1.3/20 RS sector -14.8% · RS bench -15.1% · 1Y -4.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 9.4 + 8.7 + 1.3 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17e.l.f. Beauty, Inc.ELF | 31.6/100Adverse evidence81% evidence | BREAKING OUT | 11.5/35 Revenue 24.7% · PAT -76.8% · OPM change -24.5 pp 83% evidence | 6.9/25 ROCE -3.2% · OPM -11.2% 76% evidence | 3.8/20 P/E 137.8× · PEG 5.38 65% evidence | 9.4/20 RS sector -7.5% · RS bench -9.6% · 1Y -13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 6.9 + 3.8 + 9.4 = 31.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Coty Inc.COTY | 29.7/100Adverse evidence64% evidence | TURNING | 10.3/35 Revenue -3.6% · PAT — · OPM change -7.4 pp 62% evidence | 4.1/25 ROCE -4.4% · OPM -29% 76% evidence | 8.5/20 P/E 20311× · PEG — 15% evidence | 6.8/20 RS sector -11.9% · RS bench -13.5% · 1Y -38.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 4.1 + 8.5 + 6.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Oddity Tech Ltd.ODD | 26.0/100Adverse evidence75% evidence | ASLEEP | 9.2/35 Revenue 5.1% · PAT -50.9% · OPM change -28.8 pp 83% evidence | 5.4/25 ROCE -3.9% · OPM -12.9% 76% evidence | 8.4/20 P/E 16.9× · PEG 2.29 65% evidence | 3.0/20 RS sector -55.1% · RS bench -56.8% · 1Y -73.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 5.4 + 8.4 + 3 = 26 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Unilever PLCthis pageUL | 48.4/100Thin evidence · provisional43% evidence | TURNING | 18.2/35 Revenue — · PAT — · OPM change — 12% evidence | 14.3/25 ROCE 4.9% · OPM — 61% evidence | 11.0/20 P/E 12.4× · PEG — 15% evidence | 4.9/20 RS sector -11.1% · RS bench -11.6% · 1Y -6.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 14.3 + 11 + 4.9 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Unilever PLC's stock price today?
Unilever PLC trades at $64.1, −5.8% over the past year. The company is valued at $137 B. The stock sits at 45% of its 52-week range of $55–$75, +0.6% versus its 200-day average. On the tape, the price is topping out, 1 weeks in. — as of 5 August 2026.
What were Unilever PLC's latest quarterly results?
Unilever PLC reported revenue of $20.4 B and net profit of $2.4 B for the Dec 25 quarter. Revenue fell 31.2% and profit rose 18.8% year on year. Earnings per share were $2.72. The operating margin was 18.3%, 6.7 pp higher than a year earlier. — as of 5 August 2026.
What is Unilever PLC's revenue?
Unilever PLC reported revenue of $20.4 B in the Dec 25 quarter, −31.2% year on year. For the full FY25 fiscal year, revenue was $50.5 B (−3.8%). Over the last 4 years revenue compounded at −0.9% a year. — as of 5 August 2026.
What is Unilever PLC's profit?
Unilever PLC earned $2.4 B of net profit in the Dec 25 quarter, +18.8% year on year. Full-year FY25 profit was $6.2 B. The operating margin ran 18.3% in the latest quarter. — as of 5 August 2026.
What is Unilever PLC's market cap?
Unilever PLC's market capitalisation is $137 B at a stock price of $64.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Unilever PLC pay a dividend?
No — Unilever PLC has declared no dividend per share in any of its last 8 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Unilever PLC growing?
Yes — Unilever PLC is growing: latest-quarter revenue −31.2% year on year, profit +18.8%, and the margin +6.7 pp at 18.3%. The 4-year compound rates are −0.9% (revenue) and −1.6% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Unilever PLC performing?
Unilever PLC is topping out, 1 weeks in. Its latest quarter's revenue fell 31.2% and profit rose 18.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Unilever PLC in an uptrend?
It is stalling — the price is topping out (week 1 of stage 3), trading +0.6% versus its 200-day average and at 45% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Unilever PLC beating the market?
On recent form, yes — Unilever PLC has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +20% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Unilever PLC's stock price go up?
This page publishes no price forecast for Unilever PLC. What it measures instead: the stock price is $64.1, the price is topping out 1 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Does Unilever PLC have too much debt?
It carries real leverage — Unilever PLC's debt-to-equity is 1.75. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Unilever PLC's capex?
Unilever PLC spent $4.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.4 B. — as of 5 August 2026.
What is Unilever PLC's cash flow?
Unilever PLC generated $8.3 B of operating cash flow in FY25 and $6.9 B of free cash flow after $1.4 B of capital spending. Reported profit that year was $6.2 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Unilever PLC's profit real cash?
Yes — over the last 3 fiscal years, 145% of Unilever PLC's reported profit arrived as operating cash. In FY25, operating cash was $8.3 B against reported profit of $6.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Unilever PLC?
On the balance sheet, the Z-score reads 3.07 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Unilever PLC in its business cycle?
Unilever PLC's FY25 operating margin was 17.9%, against a 5-year band of 16.6%–17.9%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 18.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Unilever PLC story?
The sharpest disagreement: annual EPS moved +67.4% against a −5.8% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Unilever PLC a stock worth studying right now?
This is not investment advice. The machine read: Unilever PLC's earnings have outrun its stock. EPS grew +67.4% in a year against a −5.8% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.